{"title":"胰腺十二指肠切除术治疗胰腺导管腺癌时术中胰腺横断缘分析和额外切除术的临床影响。","authors":"Kakeru Tawada , Yasuhiro Shimizu , Seiji Natsume , Tomonari Asano , Masataka Okuno , Seiji Ito , Koji Komori , Tetsuya Abe , Kazuo Hara , Waki Hosoda , Nobuhisa Matsuhashi","doi":"10.1016/j.pan.2024.10.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The prognostic impact of additional resection based on intraoperative frozen section analysis (FSA) of the pancreatic transection margin in patients with pancreatic ductal adenocarcinoma (PDAC) is controversial. The purpose of this study was to evaluate the prognosis based on the results of the first FSA of the pancreatic transection margin (1st FSA) and the clinical significance of additional resection.</div></div><div><h3>Methods</h3><div>Patients who underwent pancreaticoduodenectomy for PDAC from 2000 to 2020 at a single center were included. Patients were divided into 3 groups based on the 1<sup>st</sup>FSA. Survival and prognostic factors were analyzed according to the 1<sup>st</sup>FSA.</div></div><div><h3>Results</h3><div>A total of 311 patients were included in this study. The 1<sup>st</sup>FSA was negative in 272 patients (1<sup>st</sup>FSA-R0) and positive in 39 patients [carcinoma in situ (1<sup>st</sup>FSA-CIS), 21 patients; invasive carcinoma (1<sup>st</sup>FSA-IC), 18 patients]. Additional resections were performed on 37 patients [1<sup>st</sup>FSA-CIS, 20 patients; 1<sup>st</sup>FSA-IC, 17 patients], and R0 resection was achieved in 34 patients intraoperatively. Comparing median survival time to 1<sup>st</sup>FSA-R0 (36.4 months), 1<sup>st</sup>FSA-CIS was comparable (27.8 months, p = 0.276), although 1<sup>st</sup>FSA-IC was significantly worse (18.8 months, p = 0.001). On multivariate analysis, 1<sup>st</sup>FSA-IC was an independent prognostic factor (hazard ratio 2.68, 95 % confidence interval 1.16–6.17, p = 0.020).</div></div><div><h3>Conclusions</h3><div>1<sup>st</sup>FSA-CIS and 1<sup>st</sup>FSA-R0 had similar OS, implying that additional resection may be acceptable for 1<sup>st</sup>FSA-CIS. 1<sup>st</sup>FSA-IC was still an independent prognostic factor based on additional resection, and the prognostic significance of additional resection is uncertain for 1<sup>st</sup>FSA-IC.</div></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"24 7","pages":"Pages 1174-1181"},"PeriodicalIF":2.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical impact of intraoperative pancreatic transection margin analysis and additional resection during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma\",\"authors\":\"Kakeru Tawada , Yasuhiro Shimizu , Seiji Natsume , Tomonari Asano , Masataka Okuno , Seiji Ito , Koji Komori , Tetsuya Abe , Kazuo Hara , Waki Hosoda , Nobuhisa Matsuhashi\",\"doi\":\"10.1016/j.pan.2024.10.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The prognostic impact of additional resection based on intraoperative frozen section analysis (FSA) of the pancreatic transection margin in patients with pancreatic ductal adenocarcinoma (PDAC) is controversial. The purpose of this study was to evaluate the prognosis based on the results of the first FSA of the pancreatic transection margin (1st FSA) and the clinical significance of additional resection.</div></div><div><h3>Methods</h3><div>Patients who underwent pancreaticoduodenectomy for PDAC from 2000 to 2020 at a single center were included. Patients were divided into 3 groups based on the 1<sup>st</sup>FSA. Survival and prognostic factors were analyzed according to the 1<sup>st</sup>FSA.</div></div><div><h3>Results</h3><div>A total of 311 patients were included in this study. The 1<sup>st</sup>FSA was negative in 272 patients (1<sup>st</sup>FSA-R0) and positive in 39 patients [carcinoma in situ (1<sup>st</sup>FSA-CIS), 21 patients; invasive carcinoma (1<sup>st</sup>FSA-IC), 18 patients]. Additional resections were performed on 37 patients [1<sup>st</sup>FSA-CIS, 20 patients; 1<sup>st</sup>FSA-IC, 17 patients], and R0 resection was achieved in 34 patients intraoperatively. Comparing median survival time to 1<sup>st</sup>FSA-R0 (36.4 months), 1<sup>st</sup>FSA-CIS was comparable (27.8 months, p = 0.276), although 1<sup>st</sup>FSA-IC was significantly worse (18.8 months, p = 0.001). On multivariate analysis, 1<sup>st</sup>FSA-IC was an independent prognostic factor (hazard ratio 2.68, 95 % confidence interval 1.16–6.17, p = 0.020).</div></div><div><h3>Conclusions</h3><div>1<sup>st</sup>FSA-CIS and 1<sup>st</sup>FSA-R0 had similar OS, implying that additional resection may be acceptable for 1<sup>st</sup>FSA-CIS. 1<sup>st</sup>FSA-IC was still an independent prognostic factor based on additional resection, and the prognostic significance of additional resection is uncertain for 1<sup>st</sup>FSA-IC.</div></div>\",\"PeriodicalId\":19976,\"journal\":{\"name\":\"Pancreatology\",\"volume\":\"24 7\",\"pages\":\"Pages 1174-1181\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pancreatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1424390324007531\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1424390324007531","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Clinical impact of intraoperative pancreatic transection margin analysis and additional resection during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
Background
The prognostic impact of additional resection based on intraoperative frozen section analysis (FSA) of the pancreatic transection margin in patients with pancreatic ductal adenocarcinoma (PDAC) is controversial. The purpose of this study was to evaluate the prognosis based on the results of the first FSA of the pancreatic transection margin (1st FSA) and the clinical significance of additional resection.
Methods
Patients who underwent pancreaticoduodenectomy for PDAC from 2000 to 2020 at a single center were included. Patients were divided into 3 groups based on the 1stFSA. Survival and prognostic factors were analyzed according to the 1stFSA.
Results
A total of 311 patients were included in this study. The 1stFSA was negative in 272 patients (1stFSA-R0) and positive in 39 patients [carcinoma in situ (1stFSA-CIS), 21 patients; invasive carcinoma (1stFSA-IC), 18 patients]. Additional resections were performed on 37 patients [1stFSA-CIS, 20 patients; 1stFSA-IC, 17 patients], and R0 resection was achieved in 34 patients intraoperatively. Comparing median survival time to 1stFSA-R0 (36.4 months), 1stFSA-CIS was comparable (27.8 months, p = 0.276), although 1stFSA-IC was significantly worse (18.8 months, p = 0.001). On multivariate analysis, 1stFSA-IC was an independent prognostic factor (hazard ratio 2.68, 95 % confidence interval 1.16–6.17, p = 0.020).
Conclusions
1stFSA-CIS and 1stFSA-R0 had similar OS, implying that additional resection may be acceptable for 1stFSA-CIS. 1stFSA-IC was still an independent prognostic factor based on additional resection, and the prognostic significance of additional resection is uncertain for 1stFSA-IC.
期刊介绍:
Pancreatology is the official journal of the International Association of Pancreatology (IAP), the European Pancreatic Club (EPC) and several national societies and study groups around the world. Dedicated to the understanding and treatment of exocrine as well as endocrine pancreatic disease, this multidisciplinary periodical publishes original basic, translational and clinical pancreatic research from a range of fields including gastroenterology, oncology, surgery, pharmacology, cellular and molecular biology as well as endocrinology, immunology and epidemiology. Readers can expect to gain new insights into pancreatic physiology and into the pathogenesis, diagnosis, therapeutic approaches and prognosis of pancreatic diseases. The journal features original articles, case reports, consensus guidelines and topical, cutting edge reviews, thus representing a source of valuable, novel information for clinical and basic researchers alike.